(4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one
C28H25NO4 — CID 10575062
Data last refreshed: (MolForge compound catalog, from PubChem)
About (4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one
(4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one (PubChem CID 10575062) has the molecular formula C28H25NO4 and a molecular weight of 439.51 g/mol. Its IUPAC name is (4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one.
Molecular Properties
| Compound Name | (4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one |
|---|---|
| PubChem CID | 10575062 |
| Molecular Formula | C28H25NO4 |
| Molecular Weight | 439.51 g/mol |
| Exact Mass | 439.18 |
| IUPAC Name | (4S,5R)-3-[(1S)-4-oxo-2-(phenylmethoxymethyl)cyclopent-2-en-1-yl]-4,5-diphenyl-1,3-oxazolidin-2-one |
| SMILES | O=C1C=C(COCc2ccccc2)[C@@H](N2C(=O)O[C@H](c3ccccc3)[C@@H]2c2ccccc2)C1 |
| InChI | InChI=1S/C28H25NO4/c30-24-16-23(19-32-18-20-10-4-1-5-11-20)25(17-24)29-26(21-12-6-2-7-13-21)27(33-28(29)31)22-14-8-3-9-15-22/h1-16,25-27H,17-19H2/t25-,26-,27+/m0/s1 |
| InChIKey | NWQRHBZKSWCUBF-GMQQYTKMSA-N |
| XLogP | 5.41 |
| TPSA | 55.84 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 439.51 |
| LogP ≤ 5 | 5.41 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 10575062 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.